Venous Varices — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for venous varices. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
2
Active US patents
64/100
Avg vulnerability
—
Annual revenue covered

Originators in Venous Varices

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Provensis 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating venous varices. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
27
1
32

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Asclera
POLIDOCANOL
 Provensis 2 64 — 2027-11-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7814943 Asclera method of use 80 2027-11-19
9480652 Asclera formulation 48 2032-05-12

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9480652 Asclera formulation 48 2032-05-12
7814943 Asclera method of use 80 2027-11-19

Related